AVEO Oncology Initiates Pivotal Clinical Trial to Evaluate Ficlatuzumab and ERBITUX Combination Therapy for HPV-Negative Head and Neck Cancer Patients
AVEO Oncology, a subsidiary of LG Chem, has recently commenced enrollment for the FIERCE-HN trial, a highly anticipated phase 3 clinical trial. This global study aims to evaluate the efficacy and safety of AVEO s invest...
Jan 16, 2024
Clinical Study